Omnihealth Practice

Methotrexate is more hepatotoxic to patients with psoriatic disorders than those with rheumatoid arthritis

Methotrexate is a multi-acting systemic antipsoriatic drug which simultaneously inhibits purine and pyrimidine synthesis, nitric oxide production and the transcription factor nuclear-factor kappa B (NFĸB) which is an inducible transcription factor for the production of pro-inflammatory cytokines and

RHEUMATOLOGY

09 Apr 2021

Combining xanomeline with trospium as antipsychotics for schizophrenia: Reduced side effects, better drug compliance

Adherence to antipsychotics is poor due to the presence of adverse effects.¹ Xanomeline is a muscarinic receptor agonist which lacks dopaminergic activity but causes considerable cholinergic reactions.¹ In a double-blind, phase 2 randomized clinical trial, xanomeline was combined with a peripherally

PSYCHIATRY

09 Apr 2021

A low transitional-1 B cell IL-10/Tnfα ratio predicts rejection and supports preemptive intervention for patients after kidney transplantation

Renal transplantation is the optimal treatment for end-stage renal disease as it allows rehabilitation with better survival than hemodialysis or peritoneal dialysis.¹ In 2016, the annual mortality rate per 100 patient-years in Hong Kong was only 1.88 for renal transplant recipients, compared to 17.8

NEPHROLOGY

09 Apr 2021

Mental incapacity: Prepare and protect while still capable, don’t wait till it is regrettableMental incapacity: Prepare and protect while still capable, don’t wait till it is regrettable

In routine clinical practice, a treatment decision can only legally proceed after patients are adequately informed and have voluntarily granted their consent for said decision.^1,2 However, in patients whose mental capacity are compromised, a decision made on their behalf from an unauthorized third p

PSYCHIATRY

28 Feb 2021

Dr. Leung, Lam-Ming Jess

Honorary Clinical Associate Professor,
Department of Psychiatry,
Faculty of Medicine,
The Chinese University of Hong Kong

Bruton’s tyrosine kinase inhibitors delay disease progression and extend survival in patients with relapsed/refractory mantle cell lymphoma

Mantle cell lymphoma (MCL) is a B cell malignancy that is typically clinically aggressive with a poor prognosis.¹ When MCL patients progress into relapsed/refractory MCL (RRMCL), the median overall survival (OS) is usually reduced to around 1 year. Currently, three Bruton’s tyrosine kinase inhibitor

HEMATOLOGY ONCOLOGY

30 Dec 2020

Prof. Tse, Wai-Choi Eric

Clinical Professor,
Department of Medicine,
Li Ka Shing Faculty of Medicine,
The University of Hong Kong

ASH 2020

December 5-7, 2020 |

Virtual

Off-the-shelf, allogeneic SARS CoV-2 specific T-cells to treat high-risk patients with COVID-19

Treatment options for coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are currently limited.¹ Immune compromise has been identified as a major risk factor for COVID-19, resulting in reduced T-cells count with dysregulation more commonly

HEMATOLOGY

28 Feb 2021

Therapeutic options for relapsed chronic lymphocytic leukemia after frontline chemoimmunotherapy

Despite dramatic improvements in treatment outcomes over the last couple of years, chronic lymphocytic leukemia (CLL) has remained an incurable disease that requires intermittent therapy during episodes of disease progression.1 In patients with relapsed/refractory (rr) CLL, treatment options often i

HEMATOLOGY

28 Feb 2021

WCLC 2020

January 28-31, 2021 |

Virtual

Artificial intelligence platforms enable population-wide lung cancer screening programs

Lung cancer is the leading cause of cancer death worldwide that accounted for 18.4% of all cancer deaths.¹ In Hong Kong, lung cancer was associated with a crude mortality rate of 51.7% in 2018 and is considered the most common cause of cancer death.² Previously, population screening with low-dose co

ONCOLOGY RESPIROLOGY

28 Feb 2021

Monitoring biomarkers in non-small cell lung cancer patients treated with immune checkpoint inhibitors

The introduction of immune checkpoint inhibitors (ICIs) has revolutionized the approach to advanced non-small cell lung cancer (NSCLC) by offering durable disease control with less side effects than traditional chemotherapy.1 However, as most patients do not benefit from ICIs, it is important to ide

ONCOLOGY RESPIROLOGY

28 Feb 2021

AGA clinical practice guideline update: Palliative care management in patients with cirrhosis

Palliative Care (PC) is an approach to care that focuses on improving the quality-of-life of patients and their caregivers who are facing life-limiting illnesses.1 In order to meet the needs of the increasingly prevalent cirrhosis population, it is important that all clinicians are able to work toge

GASTROENTEROLOGY & HEPATOLOGY

08 Apr 2021

Semaglutide aids weight loss in adults with type 2 diabetes and reduces major adverse cardiovascular events

Weight control remains an indispensable component for the clinical management of type 2 diabetes mellitus (T2DM) in preventing cardiometabolic morbidity.1-3 People with T2DM who received weekly subcutaneous injection of semaglutide 2.4mg achieved superior and clinically meaningful reduction of body

DIABETES & ENDOCRINOLOGY

08 Apr 2021

Anti-IL-21 and liraglutide combination could preserve β-cell function in type 1 diabetes, a recent phase 2 study suggests

Being an autoimmune disease, type 1 diabetes (T1D) is characterized by the infiltration of immune cells into the pancreas that causes the destruction of insulin-producing β-cells in the pancreatic islets of Langerhans.1 While it has been the mainstay therapy for patients with T1D since its discovery

DIABETES & ENDOCRINOLOGY

08 Apr 2021

Novel oral agent effective in teens with moderate-to-severe atopic dermatitis

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin condition with immune dysfunction that affects lesional and nonlesional skin.1 Characterized by pruritus, skin pain, eczematous lesions and dry skin, AD is associated with substantial comorbidity and impairment in a patient’s quality-o

DERMATOLOGY

08 Apr 2021

The American College Of Gastroenterology publishes their first-ever IBS clinical practice guidelines

Irritable bowel syndrome (IBS) is a highly prevalent, chronic disorder that significantly reduces patients' quality of life.¹ The management of IBS has been previously examined in several recent monographs, reviews and position statements that provide management recommendations based on the meta-ana

GASTROENTEROLOGY & HEPATOLOGY

28 Feb 2021

First-line treatment with immunotherapy in metastatic squamous NSCLC

Immunotherapy has dramatically changed the therapeutic scenario in the treatment-naïve advanced NSCLC. While the single agent pembrolizumab has become the standard first-line therapy in patients with ≥50% PD-L1 expression on tumor cells,

ONCOLOGY

31 Aug 2020

Prof. Luis Paz-Ares

Head of Medical Oncology Department,
Hospital Universitario 12 de Octubre,
Madrid, Spain